These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3793503)

  • 21. Monte Carlo single-cell dosimetry of Auger-electron emitting radionuclides.
    Bousis C; Emfietzoglou D; Hadjidoukas P; Nikjoo H
    Phys Med Biol; 2010 May; 55(9):2555-72. PubMed ID: 20393237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical assessment of radiation doses using labelled antibodies for therapy.
    Myers MJ; Epenetos AA; Hooker G
    Int J Rad Appl Instrum B; 1986; 13(4):437-46. PubMed ID: 3793499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radionuclide therapy revisited.
    Hoefnagel CA
    Eur J Nucl Med; 1991; 18(6):408-31. PubMed ID: 1879447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiobiologic implications of the microscopic distribution of energy from radionuclides.
    Adelstein SJ; Kassis AI
    Int J Rad Appl Instrum B; 1987; 14(3):165-9. PubMed ID: 3312115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Principles of radioimmunotherapy for hematologists and oncologists.
    Press OW; Rasey J
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
    Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
    Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microdosimetric basis of individualized cancer radiotherapy by radionuclides including Auger effect and the photon activation approach.
    Booz J
    Strahlentherapie; 1984 Dec; 160(12):745-54. PubMed ID: 6393457
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
    Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
    Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149.
    Allen BJ; Blagojevic N
    Nucl Med Commun; 1996 Jan; 17(1):40-7. PubMed ID: 8692472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy.
    Srivastava SC
    Cancer Biother Radiopharm; 1996 Feb; 11(1):43-50. PubMed ID: 10851519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating 99mTc Auger electrons for targeted tumor radiotherapy by computational methods.
    Tavares AA; Tavares JM
    Med Phys; 2010 Jul; 37(7):3551-9. PubMed ID: 20831062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioimmunoscintigraphy and radioimmunotherapy in cancer: principles and application.
    Potamianos S; Varvarigou AD; Archimandritis SC
    Anticancer Res; 2000; 20(2A):925-48. PubMed ID: 10810378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-phase radioimmunotherapy using bispecific monoclonal antibodies (bs MAbs).
    Bosslet K; Hermentin P; Kuhlmann L; Steinstraesser A; Seemann G; Sedlacek HH
    Cancer Treat Rev; 1990 Sep; 17(2-3):355-6. PubMed ID: 2272051
    [No Abstract]   [Full Text] [Related]  

  • 34. Advances in cancer therapy with radiolabeled monoclonal antibodies.
    Goldenberg DM; Sharkey RM
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):248-64. PubMed ID: 17043623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy?
    Widel M
    Neoplasma; 2017; 64(5):641-654. PubMed ID: 28592116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
    Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
    Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Appelbaum FR
    Hematol Oncol Clin North Am; 1991 Oct; 5(5):1013-25. PubMed ID: 1938754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contributions of nuclear medicine to the therapy of malignant tumors.
    Feinendegen LE
    Strahlenther Onkol; 1991 Nov; 167(11):619-27. PubMed ID: 1962275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Perspectives in the use of monoclonal antibodies in the therapy of neoplastic diseases].
    Emmrich F
    Onkologie; 1987 Jun; 10(3):121-4. PubMed ID: 3306530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.